Description: PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
Home Page: plxpharma.com
PLXP Technical Analysis
9 Fishers Lane
Sparta,
NJ
07871
United States
Phone:
973 409 6541
Officers
| Name | Title |
|---|---|
| Mr. Michael J. Valentino | Exec. Chairman |
| Ms. Natasha Giordano | CEO, Pres & Director |
| Ms. Rita M. O'Connor CPA, CPA | CFO and Head of Manufacturing & Supply Chain |
| Mr. Ronald R. Zimmerman | Founder & Sr. Advisor |
| Mr. Tom Long | VP of Manufacturing & Technical Operations |
| Ms. Janet M. Barth | VP of Investor Relations & Corp. Communications |
| Ms. Joanne Cotignola | VP of Marketing |
| Mr. Patrick M. Lonergan | Member of Chief Exec. Officer Advisory Group |
| Mr. Charles Edmund Sheedy C.F.A., CFA | Member of Chief Exec. Officer Advisory Group |
| Mr. Harris Kaplan M.B.A., MBA | Member of Chief Exec. Officer Advisory Group |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5818 |
| Price-to-Sales TTM: | 1.2902 |
| IPO Date: | 2014-03-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |